BRENZAVVY

This brand name is authorized in United States

Active ingredients

The drug BRENZAVVY contains one active pharmaceutical ingredient (API):

1 Bexagliflozin UNII EY00JF42FV - BEXAGLIFLOZIN

Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Read about Bexagliflozin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRENZAVVY Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BK08		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 51407-826, 82381-2174